This phenomenon, called synthetic lethality, prompted clinical trials in which PARP-1 inhibitors were used as monotherapy in patients with germline BRCA-mutated ovarian or breast cancers [36,37]. This evidence concerns the gene PARP1 and breast carcinoma.